10 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts

In this article, we will take a look at the 10 stocks receiving a massive vote of approval from Wall Street analysts.

The Nasdaq 100 experienced a notable decline of 1% on February 16 as bond yields surged following the release of economic data, marking a turbulent session for investors. The data revealed that US producer prices exceeded expectations in January, contributing to concerns about inflationary pressures in the economy. On a positive note, consumer sentiment extended its upward trajectory for the third consecutive month, reflecting ongoing optimism among households. However, this optimism was overshadowed by the unexpected increase in producer prices, compounded by a drop in housing starts. The market reaction to the economic data was swift and pronounced. Bond yields, particularly those on two-year Treasury notes, surged by nine basis points to reach 4.66%, signaling heightened expectations of future monetary policy adjustments by the Federal Reserve. This increase in yields, coupled with concerns about inflation, led to a sell-off in both stocks and bonds, with the S&P 500 snapping its streak of five consecutive weeks of gains. Additionally, the dollar strengthened against major currencies, reflecting a flight to safety among investors seeking refuge from market volatility. Investors are closely monitoring the evolving economic landscape, particularly in light of the shifting expectations surrounding Federal Reserve policy. Swaps currently indicate an 85 basis points probability of Fed rate cuts this year, a significant adjustment from just two weeks ago when the market priced in around 150 basis points of cuts. This suggests that investors are reassessing their outlook for monetary policy amid changing economic conditions and signals from central bank officials. Overall, the market’s reaction to the economic data underscores the importance of data releases in shaping investor sentiment and market dynamics. As investors digest the implications of rising inflationary pressures and Fed policy expectations, volatility may persist in the near term, highlighting the need for caution and careful risk management strategies.

In January, US producer prices surged more than expected, driven largely by a significant rise in service costs, indicating persistent inflationary pressures. According to Bloomberg, the producer price index (PPI) for final demand climbed by 0.3% from the previous month, surpassing forecasts, with a year-on-year increase of 0.9%. Additionally, the core PPI, excluding volatile food and energy categories, rose by 0.5% month-on-month and 2% year-on-year, both exceeding expectations. This increase in prices was primarily driven by a surge in service categories, including hospital outpatient care and portfolio management. The release of this data led to a further selloff in Treasuries, with two-year yields reaching their highest level since mid-December. Traders adjusted their expectations for interest rate cuts, now seeing only a 25% chance of a move in May. The robust PPI figures, coupled with a recent jump in the consumer price index (CPI), suggest that the Federal Reserve may delay interest rate reductions until they are confident that inflation is under control. Economists are closely monitoring these indicators, as they inform the Fed’s preferred inflation measure, the personal consumption expenditures price gauge. With housing starts also declining in January, the economic landscape remains uncertain amid inflationary pressures and evolving Fed policy expectations.

Meanwhile, across the stock market in the U.S., stocks such as Coinbase Global, Inc. (NASDAQ:COIN) and Entegris, Inc. (NASDAQ:ENTG) are receiving a massive vote of approval from Wall Street analysts. Check out the complete article to see the details of these and other stocks.

10. Molina Healthcare, Inc. (NYSE:MOH)

Price Reaction after the Upgrade: +3.86 (+0.97%)

On February 15, Wells Fargo made a significant adjustment to its evaluation of Molina Healthcare, Inc. (NYSE:MOH), a key player in the healthcare industry. This revision marks a noteworthy development for investors and stakeholders alike. The decision to upgrade Molina Healthcare, Inc. rating from Underweight to Equal Weight suggests a shift in the perception of the company’s prospects and market position. Following Wells Fargo’s upgrade, Molina Healthcare, Inc. stock experienced a modest but notable uptick of 0.97% in its market price by the close of trading on February 15, reaching $397.93. This uptick reflects the immediate response of the market to the upgraded outlook for the company. Investors, analysts, and industry observers closely monitored this movement, considering it a reflection of shifting sentiments and expectations regarding Molina Healthcare’s future performance.

In conjunction with the rating upgrade, Wells Fargo also adjusted its price target for Molina Healthcare, Inc., raising it to $420 from the previous target of $367. This upward revision in the price target underscores Wells Fargo’s growing confidence in Molina Healthcare, Inc. ability to generate value and deliver returns to its shareholders. The new price target suggests a more optimistic outlook for the stock’s future trajectory and potential for growth within the healthcare sector. Overall, Wells Fargo’s upgraded rating and revised price target for Molina Healthcare, Inc. signal a vote of confidence in the company’s fundamentals, strategic direction, and overall prospects. This development may influence investor sentiment and contribute to reshaping perceptions of Molina Healthcare’s investment appeal and market positioning moving forward.

09. Teradyne, Inc. (NASDAQ:TER)

Price Reaction after the Upgrade: +1.11 (+1.09%)

On February 15, JPMorgan made a significant adjustment to its assessment of Teradyne, Inc. (NASDAQ:TER), a key player in the automation and testing industry. JPMorgan upgraded Teradyne, Inc. to Neutral from Underweight. Following JPMorgan’s upgrade, Teradyne, Inc. stock experienced a notable increase of 1.09% in its market price by the close of trading on February 15, reaching $102.56. This uptick reflects the immediate response of the market to the upgraded rating and highlights the market’s reaction to the changing perception of Teradyne’s prospects. In addition to upgrading its rating, JPMorgan also raised its price target for Teradyne, Inc. from $90 to $100. This upward revision in the price target underscores JPMorgan’s growing confidence in Teradyne’s potential for value creation and its ability to deliver returns to shareholders. The new price target implies a more optimistic outlook for the stock’s future performance and its position within the automation and testing sector. The decision to upgrade Teradyne, Inc. from Underweight to Neutral was driven by JPMorgan’s assessment of reduced risks facing the company. This shift in perception reflects JPMorgan’s belief that Teradyne, Inc. is better positioned to navigate challenges and capitalize on opportunities within its industry landscape. Overall, JPMorgan’s upgraded rating and revised price target for Teradyne, Inc. signal a more favorable view of the company’s fundamentals and growth prospects. This update may influence investor sentiment and contribute to shaping perceptions of Teradyne, Inc. investment attractiveness and competitive positioning in the automation and testing market.

08. Medpace Holdings, Inc. (NASDAQ:MEDP)

Price Reaction after the Upgrade: +4.54 (+1.16%)

Vulcan Value Partners stated the following regarding Medpace Holdings, Inc. in its fourth quarter 2023 investor letter:

“Medpace Holdings, Inc. (NASDAQ:MEDP) is a full service, clinical contract research organization. It provides outsourced drug development services to small and mid-sized biotechnology firms. The company is exceeding our expectations. While there continues to be funding challenges in the biotech industry, Medpace once again reported strong metrics around new business awards, revenue, earnings and most importantly free cash flow. It provided an initial guide for 2024 that came in above ours and others’ estimates, and as a result its share price responded positively. Medpace has a healthy balance sheet with no debt, a growing free cash flow coupon, and a highly aligned management team.”

07. Royal Gold, Inc. (NASDAQ:RGLD)

Price Reaction after the Upgrade: +1.68 (+1.56%)

On February 15, National Bank Financial analyst Sameer Keswani upgraded Royal Gold, Inc. (NASDAQ:RGLD) from Sector Perform to Outperform, marking a significant shift in their evaluation of the company’s prospects within the precious metals industry. This upgrade suggests that Keswani now believes Royal Gold, Inc. has the potential to outperform its sector peers and deliver superior returns to investors. The decision to upgrade the stock likely reflects a positive reassessment of Royal Gold, Inc. fundamentals, growth prospects, or strategic positioning within the market.

Following the upgrade, investors reacted positively, driving Royal Gold, Inc. stock price up by 1.56% by the closing bell on February 15, reaching $109.27. This uptick in price suggests that investors welcomed the news of the upgrade and viewed it as a validation of Royal Gold, Inc. potential. It also indicates that the market perceives the company in a more favorable light following the analyst’s revised outlook. The precious metals industry is known for its volatility and sensitivity to various factors such as economic conditions, geopolitical tensions, and fluctuations in commodity prices. Therefore, analyst recommendations play a crucial role in shaping investor sentiment and influencing stock prices within this sector. By upgrading Royal Gold, Inc. to Outperform, Keswani’s analysis may have instilled confidence in the company’s ability to navigate market challenges effectively and capitalize on opportunities for growth and profitability in the future.

06. Eversource Energy (NYSE:ES)

Price Reaction after the Upgrade: +1.56 (+2.73%)

On February 15, Mizuho Securities analyst Paul Fremont upgraded Eversource Energy (NYSE:ES) from a “neutral” rating to a “buy” rating, signaling a notable shift in sentiment toward the company within the energy sector. This upgrade reflects Fremont’s increased confidence in Eversource Energy prospects for growth and value creation. Additionally, Fremont raised the target price for the stock from $54.00 to $62.00, indicating his expectation of a higher valuation for the company in the foreseeable future. The energy industry is subject to various market dynamics, including regulatory changes, technological advancements, and shifts in consumer behavior. Fremont’s decision to upgrade Eversource Energy likely stems from his assessment of the company’s ability to capitalize on emerging opportunities and overcome potential challenges within the sector. Specifically, the anticipation of growth following the divestiture of offshore wind and water businesses could be a key driver behind Fremont’s upgraded outlook.

Investors responded positively to the upgrade, driving Eversource Energy market price up by 2.73% by the closing bell on February 15, reaching $58.62. This uptick in price suggests that investors interpreted Fremont’s upgrade as a bullish signal for Eversource Energy future performance and prospects. It also reflects a renewed investor interest in the stock, driven by the analyst’s revised rating and target price. Overall, Fremont’s upgrade of Eversource Energy underscores the importance of thorough analysis and research in shaping investment decisions within the energy sector. By providing a more optimistic outlook for the company, Fremont’s upgraded rating and target price have likely influenced investor sentiment and contributed to the stock’s positive price momentum on February 15.

05. Coinbase Global, Inc. (NASDAQ:COIN)

Price Reaction after the Upgrade: +5.29 (+3.30%)

On February 15, JPMorgan (JPM) revised its stance on Coinbase Global, Inc., a leading player in the cryptocurrency exchange industry, in response to significant developments within the crypto market. The upgrade comes amidst a notable surge in cryptocurrency prices, particularly following the approval of spot bitcoin (BTC) exchange-traded funds (ETFs) in the United States, signaling a potential shift in the industry landscape. Recognizing the impact of these developments, JPMorgan upgraded its rating on Coinbase Global, Inc. from ‘Underweight’ to ‘Neutral,’ reflecting a more balanced perspective on the company’s prospects moving forward.

The cryptocurrency industry is characterized by rapid technological advancements, regulatory changes, and market volatility, presenting both opportunities and challenges for market participants. JPMorgan’s decision to upgrade Coinbase Global, Inc. likely reflects its assessment of the company’s ability to adapt and capitalize on evolving market conditions. By shifting its rating to ‘Neutral,’ JPMorgan acknowledges the growing relevance of cryptocurrency assets and the potential for Coinbase Global, Inc. to benefit from increased market activity and investor interest. Investors responded positively to the upgrade, driving Coinbase Global, Inc. market price up by 3.30% by the closing bell on February 15, reaching $165.67. This uptick in price suggests that investors interpreted JPMorgan’s revised stance as a vote of confidence in Coinbase’s business model and growth prospects within the dynamic cryptocurrency ecosystem.  Overall, JPMorgan’s upgrade of Coinbase underscores the evolving nature of the cryptocurrency industry and the importance of adaptability in navigating market trends. By adjusting its rating to ‘Neutral’ and setting a price target of $80, JPMorgan provides investors with valuable insights into the potential trajectory of Coinbase Global, Inc. stock moving forward, while also highlighting the broader significance of recent developments in the crypto market.

Patient Capital Management stated the following regarding Coinbase Global, Inc. in its fourth quarter 2023 investor letter:

“Coinbase Global, Inc. (NASDAQ:COIN) climbed an incredible 131.7% in the quarter outpacing the 57% gain in bitcoin over the same period as investors became excited about the potential approval of a Bitcoin ETF in the new year. Coinbase continues to stand out as the lead survivor in an industry of fading and failing leaders. Cost savings initiatives taken earlier in the year have resulted in three quarters of positive EBITDA leading to expectations for “meaningful positive adjusted EBITDA” for the full year 2023. We continue to believe COIN has the potential to be the platform for crypto with $5B in liquidity providing the ability to invest and weather any crypto winters.”

04. Entegris, Inc. (NASDAQ:ENTG)

Price Reaction after the Upgrade: +4.48 (+3.42%)

On February 15, Entegris, Inc., a prominent player in the semiconductor equipment industry, received an upgrade from analyst Christian Schwab at Craig-Hallum. This upgrade came in response to the company’s robust performance in the fourth quarter of 2023, which exceeded expectations and demonstrated its strength in the market. Schwab revised Entegris, Inc. rating from ‘Hold’ to ‘Buy,’ reflecting a more optimistic outlook on the company’s future prospects. Entegris, Inc. operates within the semiconductor equipment industry, which plays a critical role in the manufacturing of semiconductors and electronic devices. As demand for advanced technology continues to grow, companies like Entegris, Inc. are well-positioned to benefit from increased investment in semiconductor production and innovation. Schwab’s decision to upgrade Entegris underscores his confidence in the company’s ability to capitalize on market opportunities and deliver strong financial performance in the coming quarters.

Investors responded positively to the upgrade, driving Entegris, Inc. market price up by 3.42% by the closing bell on February 15, reaching $135.65. This uptick in price suggests that investors interpreted Schwab’s revised stance as a vote of confidence in Entegris’ growth potential and market position. Furthermore, the upgrade may have contributed to heightened investor interest in Entegris, Inc., as it highlights the company’s positive momentum and value proposition within the semiconductor equipment industry. Overall, Schwab’s upgrade of Entegris, Inc. reflects the company’s impressive performance and outlook for continued growth. By raising the price target to $150.00 and upgrading the rating to ‘Buy,’ Schwab provides investors with valuable insights into Entegris, Inc. trajectory and reinforces the company’s position as a key player in the semiconductor equipment industry.

The London Company Mid Cap Strategy stated the following regarding Entegris, Inc. in its fourth quarter 2023 investor letter:

“Entegris, Inc. (NASDAQ:ENTG) – ENTG shares rallied during the quarter as visibility in the semiconductor market improved and demand for its value added product suite remains strong. ENTG is benefiting from the higher amount of materials needed for miniaturization and is winning business as its products deliver faster time to yield. Management has been delivering on its debt reduction strategy. We remain attracted to the industry’s high barriers to entry, limited competitors, and high switching costs.”

03. Manulife Financial Corporation (NYSE:MFC)

Price Reaction after the Upgrade: +2.16 (+9.54%)

On February 15, BMO Capital Markets analyst Tom MacKinnon made a significant upgrade to Manulife Financial Corporation (NYSE:MFC) within the automotive industry. Specifically, he upgraded the Manulife Financial Corporation stock from a “Market Perform” rating to an “Outperform” rating, signaling his increased confidence in its performance moving forward. Alongside the upgrade, MacKinnon also raised the price target for Manulife Financial Corporation from $31.00 to $35.00, indicating his bullish outlook on its potential growth and value. The automotive industry is a dynamic sector that encompasses a wide range of companies involved in the manufacturing, distribution, and sale of vehicles and related components. MacKinnon’s upgrade suggests that he believes Manulife Financial Corporation is well-positioned to outperform its peers within the industry, potentially driven by factors such as strong financial performance, favorable market conditions, or strategic initiatives. Investors reacted positively to MacKinnon’s upgrade, driving Manulife Financial Corporation market price up by an impressive 9.54% by the closing bell on February 15, reaching $24.79. This substantial increase in price indicates that investors viewed the upgrade as a bullish signal for the stock’s future prospects, prompting increased buying activity and driving up its value. Overall, MacKinnon’s upgrade and upward revision of the price target reflect his optimistic view of the stock’s potential for growth and outperformance within the automotive industry. By upgrading the stock to “Outperform” and raising the price target, MacKinnon provides investors with valuable insights and guidance, potentially attracting more interest and investment in the stock based on its positive outlook.

02. Outlook Therapeutics, Inc. (NASDAQ:OTLK)

Price Reaction after the Upgrade: +0.0645 (+15.35%)

On February 15, Chardan Capital analyst Daniil Gataulin made a notable upgrade within the pharmaceutical industry, specifically concerning Outlook Therapeutics, Inc. (NASDAQ:OTLK). Gataulin upgraded the stock’s rating from “Neutral” to “Buy,” signaling increased confidence in its future performance. Alongside this upgrade, Gataulin also announced a price target of $3 for the stock, suggesting substantial potential upside. The pharmaceutical industry encompasses companies involved in the research, development, and commercialization of drugs and medical treatments. Gataulin’s upgrade of Outlook Therapeutics, Inc. implies that he believes the company is well-positioned to deliver strong results and potentially outperform its competitors within this sector. This upgrade could be driven by various factors, such as promising clinical trial data, potential market opportunities, or positive developments in the company’s pipeline of products.

Investors responded positively to Gataulin’s upgrade, driving the stock’s market price up by a significant 15.35% by the closing bell on February 15, reaching $0.48. This substantial increase in price indicates that investors interpreted the upgrade as a bullish signal for Outlook Therapeutics, Inc., leading to increased buying activity and driving up the stock’s value. Overall, Gataulin’s upgrade and the accompanying price target announcement reflect his optimistic outlook for Outlook Therapeutics, Inc. within the pharmaceutical industry. By upgrading the stock to “Buy” and setting a price target of $3, Gataulin provides investors with valuable insights into the company’s potential for growth and value appreciation. This upgrade may attract increased interest and investment in Outlook Therapeutics, Inc. as investors consider its promising prospects.

01. Inogen, Inc. (NASDAQ:INGN)

Price Reaction after the Upgrade: +1.64 (+19.27%)

On February 15, within the medical equipment industry, William Blair analyst Margaret Kaczor made a significant upgrade regarding Inogen, Inc. (NASDAQ:INGN). Kaczor upgraded the stock’s rating from “Market Perform” to “Outperform,” indicating a more positive outlook on its future prospects. This upgrade came in response to a notable development in the industry: the announcement from Respironics that it would be exiting the U.S. portable oxygen concentrator market by the end of February 2024. Kaczor’s upgrade of Inogen, Inc. suggests that she believes the company is well-positioned to capitalize on the opportunity created by Respironics’ withdrawal from the market. With Respironics’ departure, Inogen, Inc. is expected to have the chance to capture a portion of its market share, estimated to be between 15% and 20% by William Blair.

Investors responded positively to Kaczor’s upgrade, driving up Inogen, Inc. market price by a substantial 19.27% by the closing bell on February 15, reaching $10.15. This significant increase in price reflects investors’ optimism about Inogen’s ability to benefit from the changing dynamics in the portable oxygen concentrator market. Overall, Kaczor’s upgrade and the rationale behind it signal confidence in Inogen, Inc. growth potential and market positioning within the medical equipment industry. By upgrading the stock to “Outperform” and highlighting the opportunity presented by Respironics’ withdrawal, Kaczor provides investors with valuable insights into Inogen, Inc. strategic advantage and potential for market expansion. This upgrade may attract increased interest from investors seeking exposure to the evolving landscape of medical device manufacturing and distribution.

Baron Discovery Fund made the following comment about Inogen, Inc. in its Q1 2023 investor letter:

“We exited a long-term investment in Inogen, Inc. (NASDAQ:INGN) While we like the company’s leading market position and its management team, we believe that the worldwide market for portable oxygen concentrators (which are not paid for by insurance) will be significantly constrained by the current downturn. Additionally, it appears to us that there is increased competition in the field.”

Suggested articles:

• 10 Best Augmented Reality Stocks Under $5
• 20 Fastest Growing Professions in 2024
• 10 Best Australian Stocks To Buy

This article is originally published at Insider Monkey.